,i #aaith ,,congress #ast ,session ,h4 ,r4 #ffji ,,in ,,the ,,house ,,of ,,representatives ,december #aa1 #bjbe,mr4 ,auchincloss 7for himself1 ,mrs4 ,harshbarger1 ,mr4 ,comer1 ,mr4 ,carter of ,georgia1 ,mr4 ,ciscomani1 ,mr4 ,moulton1 ,mr4 ,deluzio1 ,mr4 ,peters1 ,ms4 ,tlaib1 ,ms4 ,budzinski1 ,mr4 ,krishnamoorthi1 ,mr4 ,khanna1 ,mr4 ,lynch1 ,mr4 ,goldman of ,texas1 ,mr4 ,cohen1 ,ms4 ,pressley1 ,mr4 ,vicente ,gonzalez of ,texas1 ,mr4 ,moore of ,alabama1 ,mr4 ,subramanyam1 ,mr4 ,pocan1 ,mr4 ,bishop1 and ,ms4 ,mc,collum7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend titles ,,xi1 ,,xviii1 and ,,xix of the ,social ,security ,act to establish certain requirements under ,medicare and ,medicaid with respect to prescription drug benefits and pharmacy benefit managers4 #a4 ,short title ,this ,act may be cited as the ,pharmacists ,fight ,back in ,medicare and ,medicaid ,act4 #b4 ,establishing certain requirements with respect to ,p,b,ms 7a7 ,medicare 7#a7 ,prescription drug plans ,section #ahfj;,d-#ab of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aab7 is amended by adding at the end the following new subsection3 7h7 ,requirements relating to pharmacy benefit managers ,for plan years beginning on or after ,january #a1 #bjbg3 7#a7 ,in general ,each contract entered into with a ,,pdp sponsor under this part with respect to a prescription drug plan offered by such sponsor shall provide-- 7,a7 that the sponsor 7and any pharmacy benefit manager acting on behalf of such sponsor1 including any affiliate of such ,,pbm1 as applicable7-- 7i7 shall comply with the pharmacy payment requirements described in paragraph 7#b72 7ii7 shall comply with the rebate pass-through requirements described in paragraph 7#c72 7iii7 shall comply with the reporting requirement described in paragraph 7#d72 and 7iv7 may not engage in steering2 and 7,b7 that any pharmacy benefit manager acting on behalf of such sponsor has a written agreement with the ,,pdp sponsor under which the ,,pbm1 and any affiliate of such ,,pbm1 as applicable1 agrees to meet the requirements described in subparagraph 7,a74 7#b7 ,pharmacy payment requirements ,for purposes of paragraph 7#a77;,a77i71 the pharmacy payment requirements described in this paragraph are1 with respect to a ,,pdp sponsor 7and a ,,pbm acting on behalf of such sponsor1 including any affiliate of such ,,pbm1 as applicable7 the following3 7,a7 ,the sponsor1 ,,pbm1 or affiliate reimburses an in-network pharmacy for the ingredient cost of a covered part ,d drug in an amount equal to the sum of-- 7i7 the national average drug acquisition cost for the drug as of the day that the pharmacy submits a claim for payment for such drug 7as determined based upon the retail survey prices obtained under section #aibg7;f77#a771 or1 in the case of a drug for which no such national average drug acquisition cost is available1 the wholesale acquisition cost for such drug as of such day2 and 7ii7 an amount equal to #d percent of the amount described in clause 7i71 or #ej1 whichever is less4 7,b7 ,with respect to each covered part ,d drug obtained from an in-network pharmacy by an individual enrolled in the prescription drug plan1 the sponsor1 ,,pbm1 or affiliate-- 7i7 pays such pharmacy a dispensing fee that is equal to the dispensing fee paid for such drug under the ,state plan under title ,,xix in the ,state in which such pharmacy is located1 as reported by the ,state under section #aibg7;f77#b72 and 7ii7 does not require such individual to reimburse such dispensing fee or otherwise increase the amount owed by such individual with respect to such drug to account for such dispensing fee4 7,c7 ,the sponsor1 ,,pbm1 or affiliate does not impose any fee or other payment requirement upon an in-network pharmacy that would have the effect of reducing the amount received by the pharmacy under the other provisions of this paragraph4 7#c7 ,rebate pass-through requirements ,for purposes of paragraph 7#a77;,a77ii71 the rebate pass-through requirements described in this paragraph are1 with respect to a ,,pdp sponsor 7and a ,,pbm acting on behalf of such sponsor1 including any affiliate of such ,,pbm1 as applicable71 that1 in the case that such sponsor1 ,,pbm1 or affiliate receives a manufacturer rebate in connection with a covered part ,d drug-- 7,a7 in the case that such drug is obtained from an in-network pharmacy by an individual enrolled in the prescription drug plan1 the ,,pdp sponsor1 ,,pbm1 or affiliate applies1 at the point of sale of such drug1 a reduction to the amount of any coinsurance or copayment owed by such individual with respect to such drug1 such that the amount of coinsurance or copayment so owed is calculated based on an amount equal to the reimbursement amount for such drug determined under paragraph 7#b77;,a71 less the amount of such rebate 7or1 in the case of a rebate described in paragraph 7#e77;,b77ii71 the amount of such rebate that is attributable to such drug and such individual72 and 7,b7 in the case that the entity receiving the manufacturer rebate in connection with such drug is a ,,pbm 7or any affiliate of such ,,pbm71 the ,,pbm 7or affiliate7 remits to the ,,pdp sponsor an amount 7in this subparagraph referred to as the rebate remittance payment7 equal to the amount of such rebate 7or1 in the case of a rebate described in paragraph 7#e77;,b77ii71 the amount of such rebate that is attributable to such drug and such individual71 less the amount by which the coinsurance or copayment owed by an individual enrolled in the prescription drug plan with respect to such drug was reduced pursuant to subparagraph 7,a72 and 7,c7 in the case that such drug is obtained from an in-network pharmacy by an individual enrolled in the prescription drug plan who is a subsidy eligible individual 7as defined in section #ahfj;,d-#ad7;a77#c771 the ,,pdp sponsor remits to the ,secretary1 at such time and in such manner as the ,secretary may specify-- 7i7 in the case that the entity receiving the manufacturer rebate in connection with such drug is a ,,pbm 7or any affiliate of such ,,pbm71 the amount received by the sponsor under subparagraph 7,b7 with respect to such drug and such individual2 and 7ii7 in the case that the entity receiving the manufacturer rebate in connection with such drug is the ,,pdp sponsor1 an amount equal to the amount of such rebate 7or1 in the case of a rebate described in paragraph 7#e77;,b77ii71 the amount of such rebate that is attributable to such drug and such individual71 less the amount by which the coinsurance or copayment owed by such individual with respect to such drug was reduced pursuant to subparagraph 7,a74 7#d7 ,reporting requirement ,for purposes of paragraph 7#a77;,a77iii71 the reporting requirement described in this paragraph is1 with respect to a ,,pbm and any affiliate of such ,,pbm1 that1 not later than ,july #a1 #bjbh1 and not less frequently than annually thereafter1 the ,,pbm 7or affiliate7 submits to the ,,pdp sponsor and to the ,secretary a report containing a certification that1 during the preceding year1 such ,,pbm 7or affiliate7-- 7,a7 complied with the requirements under paragraphs 7#b7 and 7#c72 and 7,b7 did not engage in steering4 7#e7 ,definitions ,for purposes of this subsection3 7,a7 ,affiliate ,the term affiliate means1 with respect to a ,,pbm or ,,pdp sponsor1 an entity that1 directly or indirectly-- 7i7 owns1 controls1 or has an investment interest in such ,,pbm or ,,pdp sponsor2 7ii7 is owned by such ,,pbm or ,,pdp sponsor or controlled by such ,,pbm or ,,pdp sponsor2 7iii7 that such ,,pbm or ,,pdp sponsor has an investment interest in2 or 7iv7 is under common ownership or corporate control of such ,,pbm or ,,pdp sponsor4 7,b7 ,manufacturer rebate ,the term manufacturer rebate-- 7i7 means any price concession 7including any payment1 discount1 administration fee1 credit1 incentive1 or penalty7 provided by the manufacturer of a covered part ,d drug 7or any affiliate1 subsidiary1 third party1 or intermediary of such manufacturer7 to a ,,pdp sponsor 7or any ,,pbm acting on behalf of such sponsor1 including any affiliate of such ,,pbm1 as applicable71 in connection with the furnishing of such covered part ,d drug to an individual enrolled in a prescription drug plan offered by such sponsor2 and 7ii7 includes any such price concession that is determined based upon-- 7,i7 the aggregate volume of such covered part ,d drug 7or a group of covered part ,d drugs that includes such part ,d drug7 furnished to individuals enrolled in a prescription drug plan offered by such sponsor2 or 7,,ii7 the furnishing of any service provided to the manufacturer by such sponsor 7or any ,,pbm acting on behalf of such sponsor1 or any affiliate of such ,,pbm 7including an off-shore entity or group purchasing organization71 as applicable7 in connection with the furnishing of such covered part ,d drug 7or a group of covered part ,d drugs that includes such part ,d drug74 7,c7 ,pharmacy benefit manager2 ,,pbm ,the terms pharmacy benefit manager and ,,pbm mean a person1 business entity1 affiliate1 or other entity that performs pharmacy benefits management services4 7,d7 ,pharmacy benefits management services ,the term pharmacy benefits management services-- 7i7 means the managing or administration of a plan or program that pays for1 reimburses1 and covers the cost of prescription drugs and medical devices2 and 7ii7 includes the processing and payment of claims for prescription drugs and the adjudication of appeals or grievances related to qualified prescription drug coverage under this part4 7,e7 ,steering ,the term steering means1 with respect to a ,,pdp sponsor 7and any ,,pbm acting on behalf of such sponsor1 including any affiliate of such ,,pbm1 as applicable7-- 7i7 directing1 ordering1 or requiring an enrollee in a prescription drug plan to use a specific pharmacy1 including an affiliate pharmacy1 for the purpose of filling a prescription for a covered part ,d drug or receiving services from a pharmacist2 7ii7 offering or implementing a prescription drug plan design that-- 7,i7 requires an enrollee in a prescription drug plan to utilize a pharmacy1 including an affiliate pharmacy2 or 7,,ii7 increases costs to the ,,pdp sponsor or an enrollee1 including by requiring an enrollee to pay the full cost for a covered part ,d drug when such enrollee chooses not to use an affiliate pharmacy2 7iii7 advertising1 marketing1 or promoting a pharmacy1 including an affiliate pharmacy1 in a manner that encourages enrollees to choose such pharmacy over another in-network pharmacy2 7iv7 creating more than one network of pharmacies with respect to a prescription drug plan such that an in-network pharmacy belonging to a specific network 7such as a preferred pharmacy network1 narrow pharmacy network1 or specialty pharmacy network7 receives preferential treatment1 or engaging in any practice 7including accreditation or credentialing standards1 day supply limitations1 or delivery method limitations7 that has the effect of excluding an in-network pharmacy from participation in the network of the ,,pdp sponsor or restricting an in-network pharmacy from filling a prescription for a covered part ,d drug2 or 7v7 engaging in any practice that attempts to influence or induce a manufacturer of a covered part ,d drug to limit the distribution of such drug to a small number of pharmacies or certain types of pharmacies1 or to restrict distribution of such drug to non-affiliate pharmacies4 4 7#b7 ,requirement to deduct expected rebate amounts from plan bids ,section #ahfj;,d-#aa7;b77#b77;,c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7;b77#b77;,c77 is amended-- 7,a7 in clause 7iii71 by striking and at the end2 7,b7 by redesignating clause 7iv7 as clause 7v72 and 7,c7 by inserting after clause 7iii7 the following new clause3 7iv7 with respect to bids beginning with plan year #bjbg1 assumptions regarding any rebate remittance payments provided under section #ahfj;,d-#ab7;h77#c77;,b71 subtracted from the actuarial value to produce such bid2 and 4 7#c7 ,,ma-,,pd plans ,section #aheg7;f77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#bg7;f77#c77 is amended by adding at the end the following new subparagraph3 7,f7 ,requirements relating to pharmacy benefit managers ,for plan years beginning on or after ,january #a1 #bjbg1 section #ahfj;,d-#ab7;h74 4 7b7 ,medicaid 7#a7 ,in general ,section #aibg of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7 is amended-- 7,a7 in subsection 7e71 by adding at the end the following new paragraph3 7#f7 ,requirements related to pharmacy benefit managers ,a contract between the ,state and a pharmacy benefit manager1 or a contract between the ,state and a managed care entity or other specified entity 7as such terms are defined in section #aijc7m77#i77;,d7 and collectively referred to in this paragraph as the entity7 that includes provisions making the entity responsible for coverage of covered outpatient drugs dispensed to individuals enrolled with the entity1 shall require-- 7,a7 that the entity or ,,pbm 7as applicable7 does not engage in steering2 7,b7 that any payment made by the entity or the ,,pbm 7as applicable7 for such a drug and related administrative services 7as applicable71 including payments made by a ,,pbm on behalf of the ,state or entity1 is equal to-- 7i7 the ingredient cost of such drug1 which shall be in an amount equal to the sum of-- 7,i7 the national average drug acquisition cost for the drug as of the day that the pharmacy submits a claim for payment for such drug 7as determined based upon the retail survey prices obtained under subsection 7f77#a771 or1 in the case of a drug for which no such national average drug acquisition cost is available1 the wholesale acquisition cost for such drug as of such day2 and 7,,ii7 an amount equal to #d percent of the amount described in item 7aa71 or #ej1 whichever is less2 and 7ii7 a dispensing fee that is equal to the dispensing fee paid for such drug under the ,state plan under this title in the ,state in which such pharmacy is located1 as reported by the ,state under subsection 7f77#b72 and 7,c7 that1 in the case that the entity or ,,pbm 7as applicable7 receives from a manufacturer of a covered outpatient drug a rebate or discount in connection with the furnishing of such drug to an individual enrolled under the ,state plan 7or waiver of such plan71 the entity or ,,pbm remits to the ,state an amount equal to the amount of such rebate4 2 and 7,b7 in subsection 7k71 by adding at the end the following new paragraphs3 7#ac7 ,pharmacy benefit manager2 ,,pbm ,the terms pharmacy benefit manager and ,,pbm have the meaning given such terms in section #ahfj;,d-#ab7;h77,c74 7#ad7 ,steering ,the term steering has the meaning given such term in section #ahfj;,d-#ab7;h77,e71 except that any reference in such section to the ,,pdp sponsor is deemed a reference to a managed care entity or other specified entity 7as such terms are defined in section #aijc7m77#i77;,d77 that is responsible for coverage of covered outpatient drugs1 and any reference to a covered part ,d drug is deemed a reference to a covered outpatient drug4 4 7#b7 ,conforming amendments ,section #aijc7m7 of such ,act 7#db ,u4,s4,c4 #acif;b7m77 is amended-- 7,a7 in paragraph 7#b77;,a77xiii7-- 7i7 by striking and 7,,iii7 and inserting 7,,iii72 7ii7 by inserting before the period at the end the following3 1 and 7,,iv7 if the contract includes provisions making the entity responsible for coverage of covered outpatient drugs1 the entity shall comply with the requirements of section #aibg7;e77#f72 and 7iii7 by moving the margin #b ems to the left2 and 7,b7 by adding at the end the following new paragraph3 7#aj7 ,no payment shall be made under this title to a ,state with respect to expenditures incurred by the ,state for payment for services provided by an other specified entity 7as defined in paragraph 7#i77;,d77iii77 unless such services are provided in accordance with a contract between the ,state and such entity which satisfies the requirements of paragraph 7#b77;,a77xiii74 4 7#c7 ,effective date ,the amendments made by this subsection shall apply to contracts between ,states and managed care entities1 other specified entities1 or pharmacy benefit managers that have an effective date beginning on or after ,january #a1 #bjbg4 7c7 ,penalties for noncompliant ,p,b,ms 7#a7 ,criminal penalties ,section #aabh;,b of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;b7 is amended by adding at the end the following new subsection3 7i7 ,whoever provides pharmacy benefits management services on behalf of a prescription drug plan sponsor under part ,d of title ,,xviii or a medicaid managed care organization under title ,,xix and-- 7#a7 knowingly and willfully fails to comply with the pharmacy payment requirements under section #ahfj;,d-#ab7;h77#b7 or section #aibg7;e77#f77;,a71 as applicable2 7#b7 knowingly and willfully engages in steering 7as defined in section #ahfj;,d-#ab7;h772 or 7#c7 knowingly and willfully fails to comply with the rebate pass-through requirements under section #ahfj;,d-#ab7;h77#c7 or section #aibg7;e77#f77;,c71 as applicable1 shall be guilty of a felony and upon conviction thereof shall be fined not more than #a1jjj1jjj1 or imprisoned for not more than #aj years1 or both4 4 7#b7 ,civil monetary penalties ,section #aabh;,a7a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;a7a77 is amended-- 7,a7 in paragraph 7#aj71 by adding or at the end2 7,b7 by inserting after paragraph 7#aj7 the following new paragraph3 7#aa7 commits an act described in section #aabh;,b7i72 2 and 7,c7 in the first sentence-- 7i7 by striking or in cases under paragraph 7#i7 and inserting in cases under paragraph 7#i72 and 7ii7 by striking fact7 and inserting fact1 or in cases under paragraph 7#aa71 #a1jjj1jjj for each such act74 7#c7 ,effective date ,the amendments made by this subsection shall apply beginning on ,january #a1 #bjbg4 #c4 ,improving prescription drug transparency under the ,medicaid program ,section #aibg7;f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;f77 is amended-- 7#a7 in the subsection heading1 by striking retail and inserting covered outpatient drug2 and 7#b7 in paragraph 7#a7-- 7,a7 in the paragraph heading1 by striking retail and inserting covered outpatient drug2 7,b7 in subparagraph 7,a77i71 by striking retail community pharmacy and inserting pharmacy that dispenses covered outpatient drugs1 including a retail community pharmacy1 mail-order pharmacy1 specialty pharmacy1 nursing home pharmacy1 long-term care facility pharmacy1 hospital pharmacy1 or clinic pharmacy 7but not including a charitable pharmacy or a not-for-profit pharmacy72 7,c7 in subparagraph 7,c7-- 7i7 in clause 7i7-- 7,i7 by striking retail2 and 7,,ii7 by striking prescription and inserting covered outpatient2 and 7ii7 in clause 7ii71 by striking retail community2 7,d7 in subparagraph 7,d77ii71 by striking retail2 7,e7 in subparagraph 7,e71 by striking the term retail each place it appears2 and 7,f7 by adding at the end the following new subparagraphs3 7,f7 ,survey reporting ,in order to meet the requirement of section #aijb7;a77#ed71 a ,state shall require that any pharmacy in the ,state that receives any payment1 reimbursement1 administrative fee1 discount1 rebate1 or other price concession related to the dispensing of a covered outpatient drug to an individual receiving benefits under this title1 regardless of whether such payment1 reimbursement1 fee1 discount1 rebate1 or other price concession is received directly from the ,state or a managed care entity or other specified entity 7as such terms are defined in section #aijc7m77#i77;,d771 or is received indirectly from a pharmacy benefits manager or another entity that has a contract with the ,state or a managed care entity or other specified entity 7as so defined7-- 7i7 shall respond to surveys conducted under this paragraph2 and 7ii7 shall include in each such response the pharmacy's acquisition price for each such drug1 net of all such payments1 reimbursements1 administrative fees1 discounts1 rebates1 and other price concessions 7or1 in the case that the pharmacy is unable to determine the net acquisition cost for such a drug at the time that the survey is received1 the pharmacy's negotiated price for such drug74 7,g7 ,survey information ,the ,secretary shall make information on national drug acquisition prices obtained under this paragraph publicly available4 ,such information shall include at least the following3 7i7 ,the monthly response rate to the survey1 including a list of pharmacies not in compliance with subparagraph 7,f74 7ii7 ,the sampling methodology and number of pharmacies sampled monthly4 7iii7 ,information on price concessions to each pharmacy1 including discounts1 rebates1 and other price concessions1 to the extent that such information is available during the survey period4 7,h7 ,limitation on use of applicable non-retail pharmacy pricing information ,no ,state shall use pricing information reported by a pharmacy that is not a retail pharmacy to develop or inform reimbursement rates for retail community pharmacies4 4